AppliedMicro to Showcase Data Center Server Applications and Open Compute Compatible Solution on X-Gene® at OCP U.S. Summit 2016
Tweet
Share
E-mailSANTA CLARA, Calif., March 09, 2016 (GLOBE NEWSWIRE) --
WHERE: Open Compute Project Summit, San Jose Convention Center, 150 West San Carlos Street, San Jose, Calif., 95113
WHEN: March 9 – 10, 2016
WHAT: Kumar Sankaran, associate vice president, software and platform engineering at AppliedMicro, will deliver a presentation about OCP on 64-bit ARM using X-Gene® on Thursday, March 10 at 11-11:15 a.m. PST in the Expo Hall Grand Ballroom. At the company’s booth No. C11, attendees can view a variety of live demos that will highlight the company’s industry-leading technology designed to meet the unique needs of cloud and enterprise data centers, including:
- Scale-out and Scale-up computing using X-Tend™ on the OCP Compliant High Density Compute Solution using X-Gene® 2 and the Vapor IO Power Distribution Board
- CEPH on the OCP Compliant Wistron X5 Multi-Server Platform using X-Gene 1
Additional Resources
- OCP Summit page
- X-Gene resource page
- Connect with AppliedMicro via Twitter, Facebook, LinkedIn and the Blog
About AppliedMicroApplied Micro Circuits Corporation is a global leader in computing and connectivity solutions for next-generation cloud infrastructure and data centers. AppliedMicro delivers silicon solutions that dramatically lower total cost of ownership. Corporate headquarters are located in Santa Clara, California. www.apm.com.
(C) Copyright 2016, Applied Micro Circuits Corporation. AppliedMicro, X-Gene, X-Weave, Server on a Chip, and Cloud Server are registered trademarks of Applied Micro Circuits Corporation. All other product or service names are the property of their respective owners.
Media Contact: Applied Micro Circuits Corporation Mike Major Phone: (408) 542-8831 E-mail: [email protected]Source: Applied Micro Circuits Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dimensional Fund Advisors Ltd. : Form 8.3 - INTERNATIONAL PAPER CO - Ordinary Shares
- Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
- Uxin to Report Third Quarter Fiscal Year 2024 Financial Results on April 25, 2024
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
